Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632995 · ClinicalTrials.gov registry record · NA
Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 557
- Enrollment target
NCT01632995 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 557 participants.
The verdict
NCT01632995, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 557 participants
- Enrollment target
Study Summary
This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), administered at sexually transmitted disease (STD) clinics and a community health center in the United States.
Interventions
- DRUG FTC 200 mg/TDF 300 mg fixed-dose combination tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632995
The ClinicalTrials.gov registry entry for NCT01632995 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 557 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FTC 200 mg/TDF 300 mg fixed-dose combination tablet is the first listed.
NCT01632995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632995 about?
NCT01632995 is a clinical study titled "Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics". This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), administered at sexually transmitted disease (STD) clinics and a comm...
What is the current status of trial NCT01632995?
This trial is currently completed. It is a NA study. The enrollment target is 557 participants. The study started on 2012-10. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01632995?
The interventions under investigation include: FTC 200 mg/TDF 300 mg fixed-dose combination tablet (DRUG).
Who is sponsoring clinical trial NCT01632995?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.